Evidence map›Paper›PMID 35698029›Full record

ArticleBMC infectious diseases2022

Increased risk of severe COVID-19 in hospitalized patients with SARS-CoV-2 Alpha variant infection: a multicentre matched cohort study.

Guillaume Martin-Blondel, François-Xavier Lescure, Lambert Assoumou, Charlotte Charpentier, Jean-Marc Chapplain, Thomas Perpoint, Gaspard Grouteau, Hugues Cordel, Gilles Pialoux, Jérome Pacanowski and 9 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 18 institutions in 2 countries.

Guillaume Martin-BlondelService des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. martin-blondel.g@chu-toulouse.fr.
François-Xavier LescureService des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude-Bernard, APHP, Paris, France.
Lambert AssoumouSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
Charlotte CharpentierService de Virologie, Université de Paris, INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard, 75018, Paris, France.
Jean-Marc ChapplainService des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Rennes, Rennes, France.
Thomas PerpointService des Maladies Infectieuses et Tropicales, Hospices Civils de Lyon, Lyon, France.
Gaspard GrouteauService des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
Hugues CordelService des Maladies Infectieuses et Tropicales, Hôpital Avicenne, AP-HP, Bobigny, France.
Gilles PialouxService des Maladies Infectieuses et Tropicales, Hôpital Tenon, APHP, Paris, France.
Jérome PacanowskiService des Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, APHP, Paris, France.
Michael ThyService des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude-Bernard, APHP, Paris, France.
Adeline BauvoisService de Médecine Interne, Hôpital Ambroise Paré, APHP, Boulogne-Billancourt, France.
Didier LaureillardService des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Nîmes, Nîmes, France.
Fadia HamrouniSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
Michèle Algarte-GeninSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
Julien PoissyUniversity of Lille, Inserm U1285, CHU Lille, Pôle de Médecine Intensive Réanimation, CNRS, UMR 8576, UGSF, Unité de Glycobiologie Structurale et Fonctionnelle, 59000, Lille, France.
Diane DescampsService de Virologie, Université de Paris, INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard, 75018, Paris, France.
Dominique CostagliolaSorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
CoCliCo Study Group
Assistance Publique – Hôpitaux de Paris · FRSorbonne Université · FRCentre Hospitalier Universitaire de Toulouse · FRCentre National de la Recherche Scientifique · FRHôpital Ambroise-Paré · FRUniversité Claude Bernard Lyon 1 · FRInserm · FRCentre Hospitalier Universitaire de Nîmes · FRHospices Civils de Lyon · FRCentre Hospitalier Universitaire de Rennes · FRUniversité Paris Cité · FRUniversité Sorbonne Paris Nord · FRHôpital de la Croix-Rousse · FRInstitut de Virologie · FRInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement · FRInstitut Toulousain des Maladies Infectieuses et Inflammatoires · FRMère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique · FRUniversité de Lille · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe impact of the variant of concern (VOC) Alpha on the severity of COVID-19 has been debated. We report our analysis in France.

methodsWe conducted an exposed/unexposed cohort study with retrospective data collection, comparing patients infected by VOC Alpha to contemporaneous patients infected by historical lineages. Participants were matched on age (± 2.5 years), sex and region of hospitalization. The primary endpoint was the proportion of hospitalized participants with severe COVID-19, defined as a WHO-scale > 5 or by the need of a non-rebreather mask, occurring up to day 29 after admission. We used a logistic regression model stratified on each matched pair and accounting for factors known to be associated with the severity of the disease.

resultsWe included 650 pairs of patients hospitalized between Jan 1, 2021, and Feb 28, 2021, in 47 hospitals. Median age was 70 years and 61.3% of participants were male. The proportion of participants with comorbidities was high in both groups (85.0% vs 90%, p = 0.004). Infection by VOC Alpha was associated with a higher odds of severe COVID-19 (41.7% vs 38.5%-aOR = 1.33 95% CI [1.03-1.72]).

conclusionInfection by the VOC Alpha was associated with a higher odds of severe COVID-19.

Indexed as

COVID-19SARS-CoV-2AgedCohort StudiesFemaleHospitalizationHumansMaleRetrospective StudiesCOVID-19SARS-CoV-2SeverityVariant of concern Alpha

Identifiers

PMID35698029
PMCPMC9189443
OpenAlexW4282822705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.